Drug giant cancels partnership with Symphogen
![Foto: Symphogen, PR](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article6479435.ece/ALTERNATES/schema-16_9/Symphogen%2520forskning.jpg)
One of Denmark’s most ambitious biotech companies, Symphogen, has resumed full control of one of its most promising candidate drugs, the monoclonal antibody Sym004. The move signals the end of the company’s R&D pact with Germany’s Merck KGaA and Symphogen will now have to go it alone with its oncology contender.
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Drejer: The beginning of a new era
For abonnenter
Symphogen brings in new chief
For abonnenter
Symphogen in US collaboration
For abonnenter